

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- AbbVie
- Aetna
- American Academy of Dermatology
- Amgen
- Celgene
- Eli Lilly and Company
- Global Healthy Living Foundation
- GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)
- Green Mountain Care (Vermont Medicaid)
- HuskyCare (Connecticut Medicaid)
- Janssen
- MaineCare (Maine Medicaid)
- National Psoriasis Foundation
- Novartis
- Prime Therapeutics
- Valeant
- MassHealth (Massachusetts Medicaid)
- New Hampshire Medicaid Program
- Rhode Island Medicaid